Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2026 am IST			5-day change	1st Jan Change
54.35 ^USD	+11.97%		+19.79%	+84.30%

07/05	Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial	RE
06/05	Novavax beats first-quarter revenue estimates on strength in vaccine deals	RE

Moderna says CEO Stéphane Bancel's 2025 total compensation was $19.9 million - SEC filing

Published on 03/17/2026 at 03:14 am IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

07/05	Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial	RE
06/05	Novavax beats first-quarter revenue estimates on strength in vaccine deals	RE
06/05	US FDA blocked publication of COVID, shingles vaccine safety studies	RE
05/05	Vertex Pharmaceuticals Ends Study of Cystic Fibrosis Drug Over Tolerability Issues	DJ
04/05	Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC Says	MT
04/05	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
04/05	UBS Adjusts Price Target on Moderna to $45 From $36, Maintains Neutral Rating	MT
04/05	RBC Raises Price Target on Moderna to $38 From $35, Keeps Sector Perform Rating	MT
02/05	Health Care Up as Obesity-Drug Makers Regain Momentum -- Health Care Roundup	DJ
02/05	Tranche Update on Moderna, Inc.'s Equity Buyback Plan announced on August 3, 2022.	CI
02/05	Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
01/05	Morgan Stanley Raises Moderna Price Target to $33 From $30	MT
01/05	Moderna Maintains 2026 Revenue Growth Outlook as First-Quarter Results Beat Estimates	MT
01/05	Moderna, Inc., Q1 2026 Earnings Call, May 01, 2026
01/05	Exchange-Traded Funds Higher, Equity Futures Mixed Amid Continued Earnings Results	MT

Stéphane Bancel is a businessperson who has been the head of 5 different companies. Presently, he occupies the position of Chief Executive Officer & Director at Moderna, Inc., Chief Executive Officer & Director at ModernaTX, Inc. (a subsidiary of Moderna, Inc.) and Chief Executive Officer at Moderna SpA. Mr. Bancel is also on the board of 5 other companies. In his past career Stéphane Bancel occupied the position of Chairman at BG Medicine, Inc., Executive Director-Global Manufacturing Strategy at Eli Lilly & Co. Principal at Eli Lilly & Co. Ltd. and Managing Director at Eli Lilly Benelux SA (both are subsidiaries of Eli Lilly & Co.) and Chief Executive Officer for bioMérieux SA. Stéphane Bancel received a graduate degree from the University of Minnesota, a graduate degree from École Centrale Paris and an MBA from Harvard Business School.

View full profile

Chart Moderna, Inc.

Duration

Period

MRNA: Dynamic Chart

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

4,700

Sector

Pharmaceuticals

More about the company